Barclays raised the firm’s price target on Iqvia (IQV) to $185 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. Barclays says that while Iqvia’s bookings beat expectations, it is not ready to call the bottom yet on biotechs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
